Breathtec Biomedical Plans Breath Analysis Clinical Trials At Canadian Facility

(RTTNews) - Breathtec BioMedical, Inc. (BTHCF), a medical diagnostics company focused on breath analysis devices, announced Tuesday its plans for the commencement of the company's clinical trial program at Innovation Boulevard located in Surrey, British Columbia.

The latest announcement marks the beginning of an intensive research review into NA-NOSE, an advanced stage, nanotechnology-based breath analysis device from the Technion - Israel Institute of Technology which has been in-licensed by Breathtec.

The system has been developed to detect the volatile biomarkers of diseases from exhaled breath. Breathtec has chosen the Province of British Columbia and the City of Surrey to hold its clinical trials for selected respiratory infections at the Health & Technology District on Innovation Boulevard.

NA-NOSE lead researcher Professor Hossam Haick will demonstrate how the nanotechnology-based breath analysis system is used for screening of potentially life-threatening diseases.

The licensed technology will be clinically evaluated as a non-invasive point of care device for early detection of community and hospital based infections.

Breathtec CEO Guy LaTorre said, "The NA-NOSE device is an exciting new late stage technology that has already been clinically proven in the early detection of cancer and has the potential to change the way we diagnose respiratory diseases which will be our company's focus."